Skip to main content
. Author manuscript; available in PMC: 2019 Sep 27.
Published in final edited form as: Mol Pharm. 2018 May 16;15(6):2069–2083. doi: 10.1021/acs.molpharmaceut.8b00319

Table 3:

In vivo collagenase effect on nanoparticle uptake

Particle Amount of enzyme Duration of treatment Route of Injection Source Tumor Type Effect Change in ECM Ref
Caelyx® 100 µg 24 hour Tail vein Clostridiopeptidase A (Sigma) OHS osteosarcoma No change in percent area of imaged tumors exhibiting labeled liposome fluorescence No detectable change in imaged tumor SHG intensity 43
Doxil 25 or 125 µg* 20 hour Intratumoral + Intravenous Collagenase 2 (invitrogen) SCC-4 tongue sarcoma 2X increase in radiography intensity of labeled liposomes in extracted tumors at.5% dose (IT) No detectable change in SHG intensity. 35–40% reduction in IFP (under 2 hours IV) (over 2 hours IT) 60
Glycol Chitosan Nanoparticles (300 nm) 11 or 220 U/mg 72 hour Intraturmoral Collagenase Type 1 (Gibco) A549 alveolar adenocarcinoma 1.8X increase in fluorescence intensity of labeled nanoparticles in extracted tumors Visual reduction in tumor collagen by histology (not quantified) 62
Lipoplexes with CpG plasmid (150 nm) 300 µg 4 hour Intravenous Clostridium type 1 (Wako Pure Chemical) LLC lung carcinoma 1.5X increase in fluorescence intensity of labeled lipoplexes in extracted tumors 65% reduction in IFP (1 hr after collagenase injection) 63
Collagenase coated Gold nanoparticles (30 nm) <300 µg* 24 hour Intravenous Clostridium collagenase (Sigma) A549 alveolar adenocarcinoma 1.4X increase in percent injected dose of collagenase labeled gold nanoparticles by ICP-OES quantification N/A 66
*

Total dose determined assuming a 25g mouse